Free tool
FAERS Monitor: Caprelsa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022405 or its brand name (Caprelsa, Vandetanib). Reports on generic versions are filed under their own applications.
Reports
1,815
Serious
1,215
67% of reports
Hospitalization
532
Death reported
164
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea332
- rash177
- fatigue176
- electrocardiogram qt prolonged142
- hypertension115
- nausea114
- acne98
- disease progression81
- asthenia79
- blood pressure increased79
- dyspnoea77
- headache74
- death73
- decreased appetite65
- insomnia58
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2008 | 17 |
| 2009 | 21 |
| 2010 | 20 |
| 2011 | 149 |
| 2012 | 247 |
| 2013 | 119 |
| 2014 | 71 |
| 2015 | 78 |
| 2016 | 115 |
| 2017 | 62 |
| 2018 | 85 |
| 2019 | 73 |
| 2020 | 135 |
| 2021 | 150 |
| 2022 | 123 |
| 2023 | 111 |
| 2024 | 99 |
| 2025 | 78 |
| 2026 | 60 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,344 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| electrocardiogram qt prolongedSignal | 142 | 45.9 | 39.2 | 6,183 |
| acneSignal | 98 | 15.0 | 12.4 | 1,269 |
| disease progressionSignal | 81 | 7.9 | 6.4 | 487 |
| hypertensionSignal | 115 | 6.3 | 5.3 | 512 |
| blood pressure increasedSignal | 79 | 6.0 | 4.8 | 326 |
| diarrhoeaSignal | 332 | 6.0 | 5.4 | 1,409 |
| rashSignal | 177 | 4.7 | 4.1 | 524 |
| decreased appetiteSignal | 65 | 3.2 | 2.6 | 100 |
| fatigueSignal | 176 | 2.6 | 2.3 | 181 |
| insomniaSignal | 58 | 2.5 | 2.0 | 53 |
| astheniaSignal | 79 | 2.4 | 2.0 | 67 |
| nausea | 114 | 1.7 | 1.4 | 31 |
| dyspnoea | 77 | 1.6 | 1.3 | 16 |
| headache | 74 | 1.4 | 1.1 | 7 |
| death | 73 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.